File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program

TitlePopulation-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program
Authors
KeywordsCanada
Chickenpox vaccine
Health services
Herpes zoster
Hospitalization
Immunization programs
Issue Date2011
Citation
Vaccine, 2011, v. 29, n. 47, p. 8580-8584 How to Cite?
AbstractBackground: Past varicella infection (chicken pox) may reactivate into herpes zoster (shingles). Varicella vaccination leads to a reduction in cases of varicella that may in turn increase herpes zoster rates due to reduction in the immune boosting effect of exposure to varicella zoster virus against varicella reactivation. We assessed the impact of childhood varicella vaccination in Ontario, Canada on zoster incidence and healthcare visits, and established baseline zoster rates prior to zoster vaccine introduction. Methods: We used population-based, administrative databases to identify zoster incidence and healthcare use from April 1992 to March 2010. Results: After routine varicella vaccination, zoster incidence rates decreased 29% for children aged 0-9 and changed minimally for other ages. Age-standardized rates of hospitalizations during the study period declined by 53%, while outpatient rates declined by 9%. The annual zoster incidence for those 60 or older was 740 per 100,000. Conclusions: In the early post-varicella vaccination period, incidence rates of medically attended herpes zoster did not increase for the overall population and decreased moderately for children 9 years and younger, the age group targeted for varicella vaccination. © 2011 Elsevier Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/346560
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342

 

DC FieldValueLanguage
dc.contributor.authorTanuseputro, Peter-
dc.contributor.authorZagorski, Brandon-
dc.contributor.authorChan, Kevin J.-
dc.contributor.authorKwong, Jeffrey C.-
dc.date.accessioned2024-09-17T04:11:43Z-
dc.date.available2024-09-17T04:11:43Z-
dc.date.issued2011-
dc.identifier.citationVaccine, 2011, v. 29, n. 47, p. 8580-8584-
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/10722/346560-
dc.description.abstractBackground: Past varicella infection (chicken pox) may reactivate into herpes zoster (shingles). Varicella vaccination leads to a reduction in cases of varicella that may in turn increase herpes zoster rates due to reduction in the immune boosting effect of exposure to varicella zoster virus against varicella reactivation. We assessed the impact of childhood varicella vaccination in Ontario, Canada on zoster incidence and healthcare visits, and established baseline zoster rates prior to zoster vaccine introduction. Methods: We used population-based, administrative databases to identify zoster incidence and healthcare use from April 1992 to March 2010. Results: After routine varicella vaccination, zoster incidence rates decreased 29% for children aged 0-9 and changed minimally for other ages. Age-standardized rates of hospitalizations during the study period declined by 53%, while outpatient rates declined by 9%. The annual zoster incidence for those 60 or older was 740 per 100,000. Conclusions: In the early post-varicella vaccination period, incidence rates of medically attended herpes zoster did not increase for the overall population and decreased moderately for children 9 years and younger, the age group targeted for varicella vaccination. © 2011 Elsevier Ltd.-
dc.languageeng-
dc.relation.ispartofVaccine-
dc.subjectCanada-
dc.subjectChickenpox vaccine-
dc.subjectHealth services-
dc.subjectHerpes zoster-
dc.subjectHospitalization-
dc.subjectImmunization programs-
dc.titlePopulation-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2011.09.024-
dc.identifier.pmid21939721-
dc.identifier.scopuseid_2-s2.0-82455175304-
dc.identifier.volume29-
dc.identifier.issue47-
dc.identifier.spage8580-
dc.identifier.epage8584-
dc.identifier.eissn1873-2518-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats